Product Code: TMRGL85274
The report provides revenue of the global ceftriaxone market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ceftriaxone market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ceftriaxone market.
The report delves into the competitive landscape of the global ceftriaxone market. Key players operating in the global ceftriaxone market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ceftriaxone market profiled in this report.
Table of Contents
1. Preface
- 1.1. Report Scope and Market Segmentation
- 1.2. Research Highlights
2. Assumptions and Research Methodology
- 2.1. Assumptions and Acronyms Used
- 2.2. Research Methodology
3. Executive Summary
- 3.1. Market Overview
- 3.2. Introduction
4. Market Dynamics
- 4.1. Drivers
- 4.2. Restraints
- 4.3. Opportunity
- 4.4. Global Ceftriaxone Market Forecast
- 4.5. Global Ceftriaxone Market Outlook
5. Market Outlook
- 5.1. Key Market Trends
- 5.2. Regulatory Scenario, by Region
- 5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Ceftriaxone Market Analysis and Forecast, by Indication
- 6.1. Introduction
- 6.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
- 6.3. Global Ceftriaxone Market Forecast, by Indication
- 6.3.1. Urinary Tract Infections
- 6.3.2. Intra-abdominal Infections
- 6.3.3. Endocarditis
- 6.3.4. Acute Bacterial Otitis Media
- 6.3.5. Meningitis
- 6.3.6. Pneumonia
- 6.3.7. Others
7. Global Ceftriaxone Market Analysis and Forecast, by Distribution Channel
- 7.1. Introduction
- 7.2. Global Ceftriaxone Market Value Share Analysis, by Distribution Channel
- 7.3. Global Ceftriaxone Market Forecast, by Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
- 7.4. Global Ceftriaxone Market Analysis, by Distribution Channel
8. Global Ceftriaxone Market Analysis, by Region
- 8.1. Global Ceftriaxone Market Analysis, by Region
- 8.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Region
- 8.3. Global Ceftriaxone Market Forecast, by Region
- 8.3.1. North America
- 8.3.2. Europe
- 8.3.3. Asia Pacific
- 8.3.4. Latin America
- 8.3.5. Middle East & Africa
9. North America Ceftriaxone Market Analysis
- 9.1. North America Ceftriaxone Market Overview
- 9.2. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country
- 9.3. North America Ceftriaxone Market Forecast, by Country
- 9.3.1. U.S.
- 9.3.2. Canada
- 9.4. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
- 9.5. North America Ceftriaxone Market Forecast, by Indication
- 9.5.1. Urinary Tract Infections
- 9.5.2. Intra-abdominal Infections
- 9.5.3. Endocarditis
- 9.5.4. Acute Bacterial Otitis Media
- 9.5.5. Meningitis
- 9.5.6. Pneumonia
- 9.5.7. Others
- 9.6. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
- 9.7. North America Ceftriaxone Market Forecast, by Distribution Channel
- 9.7.1. Hospital Pharmacies
- 9.7.2. Retail Pharmacies
- 9.7.3. Online Pharmacies
10. Europe Ceftriaxone Market Analysis
- 10.1. Europe Ceftriaxone Market Overview
- 10.2. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
- 10.3. Europe Ceftriaxone Market Forecast, by Country/Sub-region
- 10.3.1. Germany
- 10.3.2. U.K.
- 10.3.3. France
- 10.3.4. Italy
- 10.3.5. Spain
- 10.3.6. Rest of Europe
- 10.4. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
- 10.5. Europe Ceftriaxone Market Forecast, by Indication
- 10.5.1. Urinary Tract Infections
- 10.5.2. Intra-abdominal Infections
- 10.5.3. Endocarditis
- 10.5.4. Acute Bacterial Otitis Media
- 10.5.5. Meningitis
- 10.5.6. Pneumonia
- 10.5.7. Others
- 10.6. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
- 10.7. Europe Ceftriaxone Market Forecast, by Distribution Channel
- 10.7.1. Hospital Pharmacies
- 10.7.2. Retail Pharmacies
- 10.7.3. Online Pharmacies
11. Asia Pacific Ceftriaxone Market Analysis
- 11.1. Asia Pacific Ceftriaxone Market Overview
- 11.2. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
- 11.3. Asia Pacific Ceftriaxone Market Forecast, by Country/Sub-region
- 11.3.1. China
- 11.3.2. India
- 11.3.3. Japan
- 11.3.4. Australia & New Zealand
- 11.3.5. Rest of Asia Pacific
- 11.4. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
- 11.5. Asia Pacific Ceftriaxone Market Forecast, by Indication
- 11.5.1. Urinary Tract Infections
- 11.5.2. Intra-abdominal Infections
- 11.5.3. Endocarditis
- 11.5.4. Acute Bacterial Otitis Media
- 11.5.5. Meningitis
- 11.5.6. Pneumonia
- 11.5.7. Others
- 11.6. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
- 11.7. Asia Pacific Ceftriaxone Market Forecast, by Distribution Channel
- 11.7.1. Hospital Pharmacies
- 11.7.2. Retail Pharmacies
- 11.7.3. Online Pharmacies
12. Latin America Ceftriaxone Market Analysis
- 12.1. Latin America Ceftriaxone Market Overview
- 12.2. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
- 12.3. Latin America Ceftriaxone Market Forecast, by Country/Sub-region
- 12.3.1. Brazil
- 12.3.2. Mexico
- 12.3.3. Rest of Latin America
- 12.4. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
- 12.5. Latin America Ceftriaxone Market Forecast, by Indication
- 12.5.1. Urinary Tract Infections
- 12.5.2. Intra-abdominal Infections
- 12.5.3. Endocarditis
- 12.5.4. Acute Bacterial Otitis Media
- 12.5.5. Meningitis
- 12.5.6. Pneumonia
- 12.5.7. Others
- 12.6. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
- 12.7. Latin America Ceftriaxone Market Forecast, by Distribution Channel
- 12.7.1. Hospital Pharmacies
- 12.7.2. Retail Pharmacies
- 12.7.3. Online Pharmacies
13. Middle East & Africa Ceftriaxone Market Analysis
- 13.1. Middle East & Africa Ceftriaxone Market Overview
- 13.2. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
- 13.3. Middle East & Africa Ceftriaxone Market Forecast, by Country/Sub-region
- 13.3.1. GCC Countries
- 13.3.2. South Africa
- 13.3.3. Rest of Middle East & Africa
- 13.4. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
- 13.5. Middle East & Africa Ceftriaxone Market Forecast, by Indication
- 13.5.1. Urinary Tract Infections
- 13.5.2. Intra-abdominal Infections
- 13.5.3. Endocarditis
- 13.5.4. Acute Bacterial Otitis Media
- 13.5.5. Meningitis
- 13.5.6. Pneumonia
- 13.5.7. Others
- 13.6. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
- 13.7. Middle East & Africa Ceftriaxone Market Forecast, by Distribution Channel
- 13.7.1. Hospital Pharmacies
- 13.7.2. Retail Pharmacies
- 13.7.3. Online Pharmacies
14. Competitive Analysis
- 14.1. Competition Matrix
- 14.2. Market Share Analysis, by Company, 2021
- 14.3. Company Profile
- 14.3.1. Hikma Pharmaceuticals plc
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Product Portfolio
- 14.3.1.3. Financial Overview
- 14.3.1.4. Strategic Overview
- 14.3.1.5. SWOT Analysis
- 14.3.2. Qilu Pharmaceutical Co. Ltd.
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Product Portfolio
- 14.3.2.3. Financial Overview
- 14.3.2.4. Strategic Overview
- 14.3.2.5. SWOT Analysis
- 14.3.3. Novartis AG
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Product Portfolio
- 14.3.3.3. Financial Overview
- 14.3.3.4. Strategic Overview
- 14.3.3.5. SWOT Analysis
- 14.3.4. Baxter International, Inc.
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Product Portfolio
- 14.3.4.3. Financial Overview
- 14.3.4.4. Strategic Overview
- 14.3.4.5. SWOT Analysis
- 14.3.5. Aurobindo Pharma
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Product Portfolio
- 14.3.5.3. Strategic Overview
- 14.3.5.4. SWOT Analysis
- 14.3.6. ACS DOBFAR S.P.A.
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Product Portfolio
- 14.3.6.3. Strategic Overview
- 14.3.6.4. SWOT Analysis
- 14.3.7. Orchid Pharma
- 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.7.2. Product Portfolio
- 14.3.7.3. Strategic Overview
- 14.3.7.4. SWOT Analysis
- 14.3.8. Nectar Lifesciences Ltd.
- 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.8.2. Product Portfolio
- 14.3.8.3. Financial Overview
- 14.3.8.4. Strategic Overview
- 14.3.8.5. SWOT Analysis
- 14.3.9. Lupin Pharmaceuticals, Inc.
- 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.9.2. Product Portfolio
- 14.3.9.3. Financial Overview
- 14.3.9.4. Strategic Overview
- 14.3.9.5. SWOT Analysis